1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 yearsGlobeNewsWire • 12/09/25
Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseasesGlobeNewsWire • 12/09/25
Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy TranscriptSeeking Alpha • 12/01/25
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And AdultsBenzinga • 11/25/25
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCSGlobeNewsWire • 11/25/25
Muscular Dystrophy Association Calls FDA Approval of Novartis' Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy CommunityGlobeNewsWire • 11/25/25
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)GlobeNewsWire • 11/24/25
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel GrowthZacks Investment Research • 11/21/25
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assetsGlobeNewsWire • 11/20/25
Novartis announces plans to build flagship manufacturing hub in North CarolinaGlobeNewsWire • 11/19/25
The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big BetNewsfile Corp • 11/17/25
Novartis' Phase III Malaria Study Meets Key Non-Inferiority EndpointZacks Investment Research • 11/13/25